Aadi Bioscience, Inc.

Good day and thank you for standing by. Welcome to the Addi Bioscience Third Quarter 2023 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Marcy Graham, Senior Vice President of Investor Relations and Corporate Communications, Addi Bioscience. Ms. Graham, please go ahead.

Thank you. Good morning and welcome to the Addi Bioscience conference call to provide an operational update and review results for the third quarter 2023. Joining me on the call today, Dr. David Lennon, our president and CEO, Scott Giacobbello, our CFO, and our chief medical officer, Dr. Loretta E. Tree. Today we will provide an overview of operational activity and financial results for the third quarter of 2023 and an update on our Precision 1 trial and clinical development plans going forward. We will open the line for questions at the end of the call following closing comments. A quick reminder that statements made on the call today will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors. including those set forth in the risk factors section of our annual and quarterly filings with the Securities and Exchange Commission, which can be found at www.sbc.gov or on our website at www.addibio.com. In addition, any forward-looking statements made on this call represent our views only as of today, November 8, 2023, and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. With that, I will turn the call over to our CFO, Scott Giacobbello, for his opening statement. Scott?

Thank you, Marcie, and good morning, everyone. Thank you for joining us today to review our financial and operational results for the third quarter of 2023. Before we discuss our progress in the third quarter and activities currently underway, I would like to take this opportunity to introduce Dave Lennon, who joined us as president and CEO at the start of the fourth quarter. Dave comes to us with more than 20 years of pharmaceutical leadership and deep expertise in mTOR-driven diseases, with a history in oncology and rare disease and a strong background in U.S. and global commercialization, all experiences that make him the perfect choice to guide Addy through our next phase of growth and development. I'm excited about the future and look forward to working with Dave, continuing in my role as CFO. Now I'd like to turn the call over to Dave for his initial comments. Dave?